Results 61 to 70 of about 15,808 (143)

An Unusual Case of Citrobacter koseri Infection During Pregnancy at 27 Weeks: A Case Report and Literature Review

open access: yesClinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT Early prenatal screening at 26 + 6 weeks detected Citrobacter koseri vaginal colonization in an asymptomatic high‐risk gravida. Culture‐guided IV ceftazidime (susceptible per CLSI testing) eradicated the pathogen without maternal/fetal compromise.
Mario Assenza   +2 more
wiley   +1 more source

Microbial Etiology and Antimicrobial Resistance in Pneumonia Among Hospitalized Patients in Kazakhstan: A Systematic Review and Single‐Arm Meta‐Analysis of Prevalence Data

open access: yesHealth Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Pneumonia is an inflammatory condition of the lower respiratory tract, commonly caused by infection and associated with substantial morbidity and healthcare utilization. The burden of pneumonia on healthcare is exacerbated by limited data on pathogenic causes and associated antimicrobial resistance (AMR). Here, we conducted
Radmir Sarsenov   +7 more
wiley   +1 more source

Disproportionality Analysis of Fluoroquinolone‐Associated Peripheral Neuropathy in the FAERS Database (2007–2024)

open access: yesClinical and Translational Science, Volume 19, Issue 4, April 2026.
ABSTRACT Fluoroquinolones (FQs) are among the most frequently prescribed antibiotic classes worldwide. Despite their therapeutic versatility in treating bacterial infections, regulatory authorities recognized risks of persistent and potentially irreversible adverse effects, particularly peripheral neuropathy (PN).
Nimra Shamim   +5 more
wiley   +1 more source

Ceftolozane/Tazobactam Dosing Requirements Against Bacteremia

open access: yesDose-Response, 2020
Objectives: To assess the probability of reaching adequate pharmacokinetic/pharmacodynamics values for ceftolozane/tazobactam at different doses and degrees of renal functions in patients with Pseudomonas aeruginosa bacteremia.
Jesus Ruiz   +6 more
doaj   +1 more source

Antimicrobial Resistance in Salmonella Across Aquaculture, Seafood and Related Aquatic Environments: A Scoping Review With Exploratory Textual Analysis

open access: yesReviews in Aquaculture, Volume 18, Issue 2, March 2026.
This scoping review with textual analysis maps antimicrobial resistance in Salmonella across aquaculture, seafood, and related aquatic environments. Across 93 studies, recurrent MDR patterns suggest sentinel serotypes (S. Typhimurium, S. Newport) and a minimal antimicrobial susceptibility testing (AST) panel to guide matrix‐stratified One Health ...
Cristiane Coimbra de Paula   +8 more
wiley   +1 more source

A Meta-Analysis on Clinical Outcomes of Ceftolozane versus Piperacillin in Combination with Tazobactam in Patients with Complicated Urinary Tract Infections [PDF]

open access: yes, 2022
OBJECTIVE: To evaluate efficacy and adverse events of ceftolozane/tazobactam in complicated UTI including acute pyelonephritis. METHOD: Databases that include PubMed, Embase, Scopus, and TRIP were searched.
Vippadapu, Prasanna   +5 more
core   +1 more source

Broadly Defined Antibiotic Adjuvants for Pseudomonas aeruginosa

open access: yesCanadian Journal of Infectious Diseases and Medical Microbiology, Volume 2026, Issue 1, 2026.
Pseudomonas aeruginosa is a widely distributed opportunistic pathogen with multiple drug resistance, making it particularly challenging to treat in lower respiratory tract infections. Its resistance mechanisms are complex, including low outer‐membrane permeability, efflux pump overexpression, biofilm formation, and quorum sensing (QS) activation ...
Zhihan Chen   +3 more
wiley   +1 more source

Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital [PDF]

open access: yes, 2019
Objectives. Our objective was to evaluate the in vitro activity of ceftolozane-tazobactam against multidrug resistant (MDR) and extensively drug-resistant (XDR) non metallo-ß-lactamase producing Pseudomonas aeruginosa clinical isolates at Hospital ...
Rezusta Lopez, Antonio   +8 more
core  

Ceftolozane–tazobactam in an elastomeric infusion device for ambulatory care: an in vitro stability study

open access: yes, 2019
Objectives: Published in vitro stability data for ceftolozane-tazobactam supports intermittent short duration infusions. This method of delivery is not feasible for many outpatient antimicrobial therapy services that provide only one or two visits per ...
Raby, Edward   +13 more
core   +1 more source

Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation [PDF]

open access: yes, 2016
Ceftolozane-tazobactam has potent activity against Pseudomonas aeruginosa , a pathogen associated with cystic fibrosis (CF) acute pulmonary exacerbations (APE).
Muhlebach, Marianne   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy